Abnormal circulating levels of metalloprotease 9 and its tissue inhibitor 1 in angiographically proven peripheral arterial disease: Relationship to disease severity

Journal of Internal Medicine

Volumn 257, Issue 1, 2005, Pages 110-116

  Tayebjee, M H ^a   Tan, K T ^a   MacFadyen, R J ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Matrix metalloproteinase 9; Peripheral arterial disease; Tissue inhibitor of matrix metalloproteinase 1

Indexed keywords

METALLOPROTEINASE; METALLOPROTEINASE 9; TISSUE INHIBITOR OF METALLOPROTEINASE; UNCLASSIFIED DRUG;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTERY DISEASE; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE MARKER; DISEASE SEVERITY; ENZYME BLOOD LEVEL; ENZYME DEGRADATION; EXTRACELLULAR MATRIX; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; INTERMITTENT CLAUDICATION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PERIPHERAL CIRCULATION; PRIORITY JOURNAL;

AGED; FEMALE; HUMANS; INTERMITTENT CLAUDICATION; ISCHEMIA; LEG; LIPOPROTEINS, HDL; MALE; MATRIX METALLOPROTEINASE 9; PERIPHERAL VASCULAR DISEASES; SEVERITY OF ILLNESS INDEX; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 12344263631     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2004.01431.x     Document Type: Article

References (23)

1. Coffman J. Pathophysiology of obstructive arterial disease. Herz 1988; 13: 343-50.
2. McCawley L, Matrisian L. Matrix metalloproteinases: they are not just for matrix anymore! Curr Opin Cell Biol 2001; 13: 534-40.
3. Deafawe O, Colige A, Lambert C et al. TIMP-2 and PAI-1 mRNA levels are lower in aneurysmal as compared to atheroocclusive abdominal aortas. Cardiovasc Res 2003; 60: 205-13.
4. Longo G, Xiong W, Greiner T, Zhao Y, Fiotti N, Baxter B. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest 2002; 110: 625-32.
5. Beard J. ABC of arterial and venous disease: chronic lower limb ischaemia. BMJ 2000; 320: 854-7.
6. Muhs B. Flits G, Delgado Y et al. Temporal expression and activation of matrix metalloproteinases-2, -9. and membrane type 1 - matrix metalloproteinase following acute hindlimb ischemia. J Surg Res 2003; 111: 8-15.
7. Faia K. Davis W, Marone A, Foxall T. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in hamster aortic atherosclerosis: correlation with in situ zymography. Atherosclerosis 2002; 160: 325-37.
8. Beaudeux J, Giral P, Bruckert E, Bernard M, Foglietti M, Chapman M. Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 as potential markers of carotid atherosclerosis in infraclinical hyperlipidemia. Atherosclerosis 2003; 169: 139-46.
9. De Smet B, de Kleijn D, Hamemaaijer R et al. Metalloproteinase inhibition reduces constrictive arterial remodeling after balloon angioplasty - a study in the atherosclerotic Yucatan micropig. Circulation 2000; 101: 2962-7.
10. Inokubo Y, Hanada H, Ishizaka H, Fukushi T, Kamada T, Okumura K. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J 2001; 141: 211-7.
11. Noji Y, Kajinami K, Kawashiri MA et al. Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis. Clin Chem Lab Med 2001; 39: 380-4.
12. Loftus I, Naylor A, Goodall S et al. Increased matrix metalloproteinase-9 activity in unstable carotid plaques - a potential role in acute plaque disruption. Stroke 2000; 31: 40-7.
13. Galis Z, Sukhova G, Lark M. Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94: 2493-503.
14. Kalela A. Koivu T. Sisto T et al. Serum matrix metalloproteinase-9 concentration in angiographically assessed coronary artery disease. Scand J Clin Lab Invest 2002; 65: 337-42.
15. Blankenberg S, Rupprecht HJ, Poirier O et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003; 107: 1579-85.
16. Lindsey M, Wedin K, Brown M et al. Matrix-dependent mechanism of neutrophil-mediated release and activation of matrix metalloproteinase 9 in myocardial ischemia/reperfusion. Circulation 2001; 103: 2181-7.
17. Carney DE, Lutz CJ, Picone AL et al. Matrix metalloproteinase inhibitor prevents acute lung injury after cardiopulmonary bypass. Circulation 1999; 100: 400-6.
18. Steinberg J, Fink G, Picone A et al. Evidence of increased matrix metalloproteinase-9 concentration in patients following cardiopulmonary bypass. J Extra Corpor Technol 2001; 33: 218-22.
19. Zaltsman A, George S, Newby A, Increased secretion of tissue inhibitors of metalloproteinases 1 and 2 from the aortas of cholesterol fed rabbits partially counterbalances increased metalloproteinase activity. Arteriosckr Thromb Vasc Biol 1999; 19: 1700-7.
20. Tayebjee M. MacFadyen RJ, Lip GYH. Extracellular matrix biology: a new frontier in linking the pathology and therapy of hypertension? J Hypertens 2003; 21: 2211-8.
21. Mutsaers S. Bishop J, McGrouther G, Laurent G. Mechanisms of tissue repair: from wound healing to fibrosis. Int J Biochem Cell Biol 1997; 29: 5-17.
22. Haas T. Madri J. Extracellular matrix-driven matrix metallo-proteinase production in endothelial cells: implications for angiogenesis. Trends Cardiovasc Med 1999; 9: 70-7.
23. Burton J, Wells M. The Alder Hey affair. Arch Dis Child 2002; 86: 4-7.